Chromosomal aberrations and fusion genes in myeloid malignancies

References

• Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 112(13), 4808–4817 (2008).
   PubMed Web of Science ®Google Scholar
• De Keersmaecker K, Cools J. Chronic myeloproliferative disorders: a tyrosine kinase tale. Leukemia 20(2), 200–205 (2006).
   PubMed Web of Science ®Google Scholar
• Lierman E, Cools J. Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia. Expert Rev. Anticancer Ther. 9(9), 1295–1304 (2009).
   PubMed Web of Science ®Google Scholar
• Bain BJ. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. Haematologica 95(5), 696–698 (2010).
   PubMed Web of Science ®Google Scholar
• Scandura JM, Boccuni P, Cammenga J, Nimer SD. Transcription factor fusions in acute leukemia: variations on a theme. Oncogene 21(21), 3422–3444 (2002).
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Cortes J. Molecular biology of BCR–ABL1-positive chronic myeloid leukemia. Blood 113(8), 1619–1630 (2009).
   PubMed Web of Science ®Google Scholar
• Petzer AL, Wolf D, Fong D et al. High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR–ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG Phase III CML 11 ‘ISTAHIT’ study. Haematologica 95(6), 908–913 (2010).
   PubMed Web of Science ®Google Scholar
• Shah NP, Kim DW, Kantarjian H et al. Potent, transient inhibition of BCR–ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 95(2), 232–240 (2010).
   PubMed Web of Science ®Google Scholar
• Wasag B, Lierman E, Meeus P, Cools J, Vandenberghe P. The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11). Haematologica 96(6), 922–926 (2011).
   PubMed Web of Science ®Google Scholar
• Lierman E, Folens C, Stover EH et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFR-α and the imatinib-resistant FIP1L1-PDGFR-α T674I mutant. Blood 108(4), 1374–1376 (2006).
   PubMed Web of Science ®Google Scholar
• Lierman E, Michaux L, Beullens E et al. FIP1L1-PDGFR-α D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFR-α T674I eosinophilic leukemia with single agent sorafenib. Leukemia 23(5), 845–851 (2009).
   PubMed Web of Science ®Google Scholar
• Deschler B, Lübbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer 107(9), 2099–2107 (2006).
   PubMed Web of Science ®Google Scholar
• Bennett JM, Catovsky D, Daniel MT et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French–American–British Cooperative Group. Ann. Intern. Med. 103(4), 620–625 (1985).
   PubMed Web of Science ®Google Scholar
• Swerdlow SH; Cancer IAFRO, WHO. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO, Geneva, Switzerland (2008).
   Google Scholar
• van Dongen JJ, Macintyre EA, Gabert JA et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 13(12), 1901–1928 (1999).
   PubMed Web of Science ®Google Scholar
• Beillard E, Pallisgaard N, van der Velden VH et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program. Leukemia 17(12), 2474–2486 (2003).
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Oliver F et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood 92(7), 2322–2333 (1998).
   PubMed Web of Science ®Google Scholar
• Slovak ML, Kopecky KJ, Cassileth PA et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96(13), 4075–4083 (2000).
   PubMed Web of Science ®Google Scholar
• Byrd JC, Mrózek K, Dodge RK et al.; Cancer and Leukemia Group B (CALGB 8461). Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100(13), 4325–4336 (2002).
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey EH, Amadori S et al.; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115(3), 453–474 (2010).
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Cuneo A, Pane F et al.; Acute Leukemia Working Party of the GIMEMA group. Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. Haematologica 93(7), 1017–1024 (2008).
   PubMed Web of Science ®Google Scholar
• Döhner H, Gaidzik VI. Impact of genetic features on treatment decisions in AML. Hematology, Am. Soc. Hematol. Educ. Program 2011(1), 36–42 (2011).
   PubMedGoogle Scholar
• Patel JP, Gönen M, Figueroa ME et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N. Engl. J. Med. 366(12), 1079–1089 (2012).
   PubMed Web of Science ®Google Scholar
• Grimwade D, Hills RK, Moorman AV et al.; National Cancer Research Institute Adult Leukaemia Working Group. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116(3), 354–365 (2010).
   PubMed Web of Science ®Google Scholar
• Haferlach C, Alpermann T, Schnittger S et al. Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype. Blood 119(9), 2122–2125 (2012).
   PubMed Web of Science ®Google Scholar
• Haferlach C, Dicker F, Herholz H, Schnittger S, Kern W, Haferlach T. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia 22(8), 1539–1541 (2008).
   PubMed Web of Science ®Google Scholar
• Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science 319(5868), 1352–1355 (2008).
   PubMed Web of Science ®Google Scholar
• Cavelier C, Didier C, Prade N et al. Constitutive activation of the DNA damage signaling pathway in acute myeloid leukemia with complex karyotype: potential importance for checkpoint targeting therapy. Cancer Res. 69(22), 8652–8661 (2009).
   PubMed Web of Science ®Google Scholar
• Melnick A, Licht JD. Deconstructing a disease: RAR-α, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93(10), 3167–3215 (1999).
   PubMed Web of Science ®Google Scholar
• Dilworth FJ, Chambon P. Nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription. Oncogene 20(24), 3047–3054 (2001).
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Ammatuna E. The biology of acute promyelocytic leukemia and its impact on diagnosis and treatment. Hematol. Am Soc. Hematol. Educ. Program. 514, 156–161 (2006).
   Google Scholar
• Ablain J, de The H. Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood 117(22), 5795–5802 (2011).
   PubMed Web of Science ®Google Scholar
• Sanz MA, Lo-Coco F. Modern approaches to treating acute promyelocytic leukemia. J. Clin. Oncol. 29(5), 495–503 (2011).
   PubMed Web of Science ®Google Scholar
• Avvisati G, Lo-Coco F, Paoloni FP et al.; GIMEMA, AIEOP, and EORTC Cooperative Groups. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood 117(18), 4716–4725 (2011).
   PubMed Web of Science ®Google Scholar
• Breccia M, Cicconi L, Minotti C, Latagliata R, Giannì L, Lo-Coco F. Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia. Haematologica 96(9), 1390–1391 (2011).
   PubMed Web of Science ®Google Scholar
• Shen ZX, Shi ZZ, Fang J et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc. Natl Acad. Sci. USA 101(15), 5328–5335 (2004).
   PubMed Web of Science ®Google Scholar
• Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84(2), 321–330 (1996).
   PubMed Web of Science ®Google Scholar
• Sasaki K, Yagi H, Bronson RT et al. Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor b. Proc. Natl Acad. Sci. USA 93(22), 12359–12363 (1996).
   PubMed Web of Science ®Google Scholar
• Lichtinger M, Hoogenkamp M, Krysinska H, Ingram R, Bonifer C. Chromatin regulation by RUNX1. Blood Cells Mol. Dis. 44(4), 287–290 (2010).
   PubMed Web of Science ®Google Scholar
• Bakshi R, Hassan MQ, Pratap J et al. The human SWI/SNF complex associates with RUNX1 to control transcription of hematopoietic target genes. J. Cell. Physiol. 225(2), 569–576 (2010).
   PubMed Web of Science ®Google Scholar
• Reikvam H, Hatfield KJ, Kittang AO, Hovland R, Bruserud Ø. Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications. J. Biomed. Biotechnol. 2011, 104631 (2011).
   PubMedGoogle Scholar
• Miyoshi H, Shimizu K, Kozu T, Maseki N, Kaneko Y, Ohki M. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc. Natl Acad. Sci. USA 88(23), 10431–10434 (1991).
   PubMed Web of Science ®Google Scholar
• Hug BA, Lazar MA. ETO interacting proteins. Oncogene 23(24), 4270–4274 (2004).
   PubMed Web of Science ®Google Scholar
• Rhoades KL, Hetherington CJ, Rowley JD et al. Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis. Proc. Natl Acad. Sci. USA 93(21), 11895–11900 (1996).
   PubMed Web of Science ®Google Scholar
• Tonks A, Pearn L, Musson M et al. Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia. Leukemia 21(12), 2495–2505 (2007).
   PubMed Web of Science ®Google Scholar
• Roudaia L, Cheney MD, Manuylova E et al. CBF-b is critical for AML1-ETO and TEL-AML1 activity. Blood 113(13), 3070–3079 (2009).
   PubMed Web of Science ®Google Scholar
• Yan M, Ahn EY, Hiebert SW, Zhang DE. RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis. Blood 113(4), 883–886 (2009).
   PubMed Web of Science ®Google Scholar
• Kwok C, Zeisig BB, Qiu J, Dong S, So CW. Transforming activity of AML1-ETO is independent of CBFb and ETO interaction but requires formation of homo-oligomeric complexes. Proc. Natl Acad. Sci. USA 106(8), 2853–2858 (2009).
   PubMed Web of Science ®Google Scholar
• Lukasik SM, Zhang L, Corpora T et al. Altered affinity of CBFβ-SMMHC for Runx1 explains its role in leukemogenesis. Nat. Struct. Biol. 9(9), 674–679 (2002).
   PubMedGoogle Scholar
• Marcucci G, Mrózek K, Ruppert AS et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J. Clin. Oncol. 23(24), 5705–5717 (2005).
   PubMed Web of Science ®Google Scholar
• Corsello SM, Roti G, Ross KN et al. Identification of AML1-ETO modulators by chemical genomics. Blood 113(24), 6193–6205 (2009).
   PubMed Web of Science ®Google Scholar
• Klisovic MI, Maghraby EA, Parthun MR et al. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia 17(2), 350–358 (2003).
   PubMed Web of Science ®Google Scholar
• Gozzini A, Santini V. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts. Ann. Hematol. 84(Suppl. 1), 54–60 (2005).
   PubMed Web of Science ®Google Scholar
• Tabe Y, Jin L, Contractor R et al. Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1. Cell Death Differ. 14(8), 1443–1456 (2007).
   PubMed Web of Science ®Google Scholar
• Liu S, Klisovic RB, Vukosavljevic T et al. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells. J. Pharmacol. Exp. Ther. 321(3), 953–960 (2007).
   PubMed Web of Science ®Google Scholar
• Duque-Afonso J, Yalcin A, Berg T, Abdelkarim M, Heidenreich O, Lübbert M. The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO. Oncogene 30(27), 3062–3072 (2011).
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B et al. Phase 1/2 study of the combination of 5-aza-2´-deoxycytidine with valproic acid in patients with leukemia. Blood 108(10), 3271–3279 (2006).
   PubMed Web of Science ®Google Scholar
• Gojo I, Jiemjit A, Trepel JB et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 109(7), 2781–2790 (2007).
   PubMed Web of Science ®Google Scholar
• Odenike OM, Alkan S, Sher D et al. Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. Clin. Cancer Res. 14(21), 7095–7101 (2008).
   PubMed Web of Science ®Google Scholar
• Gorczynski MJ, Grembecka J, Zhou Y et al. Allosteric inhibition of the protein-protein interaction between the leukemia-associated proteins Runx1 and CBfFb. Chem. Biol. 14(10), 1186–1197 (2007).
   PubMed Web of Science ®Google Scholar
• Racanicchi S, Maccherani C, Liberatore C et al. Targeting fusion protein/corepressor contact restores differentiation response in leukemia cells. EMBO J. 24(6), 1232–1242 (2005).
   PubMed Web of Science ®Google Scholar
• Wichmann C, Chen L, Heinrich M et al. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells. Cancer Res. 67(5), 2280–2289 (2007).
   PubMed Web of Science ®Google Scholar
• Heidenreich O, Krauter J, Riehle H et al. AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells. Blood 101(8), 3157–3163 (2003).
   PubMed Web of Science ®Google Scholar
• Kasashima K, Sakota E, Kozu T. Discrimination of target by siRNA: designing of AML1-MTG8 fusion mRNA-specific siRNA sequences. Biochimie 86(9–10), 713–721 (2004).
   PubMed Web of Science ®Google Scholar
• Dunne J, Cullmann C, Ritter M et al. siRNA-mediated AML1/MTG8 depletion affects differentiation and proliferation-associated gene expression in t(8;21)-positive cell lines and primary AML blasts. Oncogene 25(45), 6067–6078 (2006).
   PubMed Web of Science ®Google Scholar
• Zeleznik-Le NJ, Harden AM, Rowley JD. 11q23 translocations split the ‘AT-hook’ cruciform DNA-binding region and the transcriptional repression domain from the activation domain of the mixed-lineage leukemia (MLL) gene. Proc. Natl Acad. Sci. USA 91(22), 10610–10614 (1994).
   PubMed Web of Science ®Google Scholar
• Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat. Rev. Cancer 7(11), 823–833 (2007).
   PubMed Web of Science ®Google Scholar
• Tamai H, Inokuchi K. 11q23/MLL acute leukemia: update of clinical aspects. J. Clin. Exp. Hematop. 50(2), 91–98 (2010).
   PubMedGoogle Scholar
• Yokoyama A, Kitabayashi I, Ayton PM, Cleary ML, Ohki M. Leukemia proto-oncoprotein MLL is proteolytically processed into 2 fragments with opposite transcriptional properties. Blood 100(10), 3710–3718 (2002).
   PubMed Web of Science ®Google Scholar
• Grembecka J, Belcher AM, Hartley T, Cierpicki T. Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias. J. Biol. Chem. 285(52), 40690–40698 (2010).
   PubMed Web of Science ®Google Scholar
• Liedtke M, Cleary ML. Therapeutic targeting of MLL. Blood 113(24), 6061–6068 (2009).
   PubMed Web of Science ®Google Scholar
• Daigle SR, Olhava EJ, Therkelsen CA et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20(1), 53–65 (2011).
   PubMed Web of Science ®Google Scholar